The Canadian Agency for Drugs and Technologies in Health, the Canadian entity responsible for health technology assessments (HTAs), has released a new report that explores international policies related to biosimilars and the factors that facilitate their use.
The Canadian Agency for Drugs and Technologies in Health (CADTH), the Canadian entity responsible for health technology assessments, has released a new report that explores international policies related to biosimilar and the factors that facilitate their use.
According to CADTH, during 2016, the 30 top-selling biologics in Canada accounted for 24% of all pharmaceutical sales in the country, but 13 biologics could face biosimilar competition in Canada within the next 3 years, with a potential to generate substantial savings. “However, for a health care system to realize these cost savings, successful market uptake of biosimilars will depend on various factors, such as number and timing of entrants into the market, patient and health care provider’s understanding and acceptance of biosimilars versus biologics, cost of biosimilars, pricing policies, payer coverage and utilization policies, and policies around interchangeability and substitution,” wrote CADTH, and the report seeks to identify the international policies best suited to providing a context favorable to biosimilar use.
The report’s authors relied on literature in Medline, Embase, PubMed, and the Cochrane Library, and present findings on 4 postmarket-related policies for the United States, Australia, New Zealand, Finland, France, Germany, the Netherlands, Norway, and the United Kingdom.
Interchangeability, Switching, and Substitution
While the United States is the only nation to hold a legal definition of interchangeability that guides pharmacy-level substitution, a variety of other policies exist worldwide. In the United Kingdom, switching is managed at the providers’ discretion, and substitution at the pharmacy level is not recommended. In Germany, prescriber-led switching is encouraged. In France, patients can be switched at any time, but pharmacy-level substitution can only take place for treatment-naïve patients and with notification to the prescriber. The Netherlands permits new patients to receive biosimilars immediately, but leaves the decision to switch to prescribers. Norway similarly leaves the decision to switch to prescribers, but considers switching among reference products and biosimilars safe at any time in treatment. While automatic substitution is not permitted in Finland, switching among biosimilars and the reference at any time is permitted so long as documentation is provided. In Australia, the government actively encourages the use of biosimilars for treatment-naïve patients, and physicians may choose to switch established patients. Pharmacy-level substitution is permitted for some products. No substitution is permitted in New Zealand, where the decision to switch remains with the clinician.
Supply-Side Policies
Free pricing policies are in place for biosimilars in the United States and United Kingdom, but UK policies subject biosimilars to the Pharmaceutical Price Regulation Scheme, which sets price ceilings. The UK system also makes use of tendering procedures in both the outpatient and hospital pharmacy contexts.
In Germany, which uses internal reference pricing, the costs for biosimilars cannot exceed the cost of the reference biologic, and insurance plans can negotiate prices through tenders. German patients also must pay the difference between the retail price and the reference reimbursement price, incentivizing patients to choose cheaper products.
In France, biosimilar prices are negotiated between pharmaceutical companies and the government, with a compulsory discount on biosimilars that ranges from 10% to 20%. The Netherlands uses a reference pricing system for biosimilars, setting the price of the biosimilar at the same price as the reference. However, tenders are used to generate further discounts. In Norway, the price of a biosimilar cannot exceed that of the reference, and mandatory discounts increase with time and the number of market entrants. Finland caps the price of the first reimbursable biosimilar at a 30% discount to the reference, and the prices of the reference biologics are renegotiated once a biosimilar has launched.
Beginning in October 2018, Australia put in place a mandatory discount of 25% on the price of the reference when a biosimilar is introduced. As an incentive to prescribe cheaper drugs, pharmacists are currently allowed to keep the difference when dispensing medicines that are cheaper than the government’s reimbursement price.
Prescribing Incentives
While no prescribing incentives are in place in the United States, new Medicare Part B reimbursement rules could provide an indirect incentive to physicians to prescribe biosimilars. Meanwhile, in the United Kingdom, providers and clinical commissioners have entered into gain-share agreements that allow health systems to keep a portion of cost savings from using biosimilars. Germany uses a similar approach, and also sets national, regional, and local prescribing quotas for some biosimilars. Additionally, German physicians who exceed their pharmaceutical budget substantially must repay the amount about 115% if no justification can be provided.
France is expected to implement a new framework to promote biosimilars by setting up new contracts with hospitals, but currently, no specific policies are in place. By contrast, Finland and Norway compel physicians to choose the least expensive products.
Australia offers a faster and simpler preapproval process for biosimilars while maintaining higher requirements for reference biologics, although prescribers remain in control of which drugs are prescribed.
Promotion and Education
In the United States, both the FDA and industry are engaged in efforts to educate stakeholders, and likewise, the European Medicines Agency has published a range of informational materials.
The United Kingdom has also produced a commissioning framework for biologic medicines, and drug-specific clinical practice guidelines also facilitate the use of biosimilars. In Germany, France, Norway, and the Netherlands, specific educational programs focus on physician awareness. In Australia, the government has launched an awareness initiative that targets both providers and patients.
While the report identified a number of policy options for the Canadian healthcare system, wrote CADTH, “Whether similar policy mechanisms can be applied in the Canadian setting will depend on a complex interplay of factors and the coordinated engagement of a number of stakeholders.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.